Federal Judge Allows Biocon to Enter U.S. Market with Eylea Biosimilar Starting 2026 After Patent Settlement

In a recent legal development, a federal judge in West Virginia has lifted a permanent injunction that had been preventing Biocon Biologics Inc. from selling its biosimilar product of Regeneron’s eye medication, Eylea, within the United States. This decision follows a settlement agreement reached in the ongoing patent litigation, which now permits the sales of Biocon’s biosimilar starting in 2026. For further details on this legal proceeding, you can read more at the Law360 article.